





THE LARGEST ADJUVANT BREAST CANCER TREATMENT CLINICAL TRIAL EVER COMPLETED

TAILORx Study with the Oncotype DX® test¹

Results published in The New England Journal of Medicine



Based on **PRACTICE-CHANGING RESULTS** from the TAILORx study, we now have definitive clarity on how the Oncotype DX® test identifies patients who will or will not benefit from chemotherapy.



Oncotype DX Breast Recurrence Score® test



Recurrence Score® result

*Exploratory analysis indicates women ≤50 years with Recurrence Score® results 16-20 have -1.6% benefit from chemotherapy and those with Recurrence Score® results 21-25 have -6.5% benefit with chemotherapy (in reducing the risk of the cancer's returning within 9 years after surgery)



With this **highest level** of evidence, early stage HR+, HER2-, node-negative early breast cancer patients with an Oncotype DX Breast Recurrence Score® result can know whether chemotherapy will reduce the risk of the cancer's returning after surgery.

¹ Sparano et al. *N Engl J Med*. 2018.

Exact Sciences is unable to advise you on your diagnosis or treatment plan. Such matters should be discussed with your healthcare professional. Oncotype DX Breast Recurrence Score, Oncotype DX and Recurrence Score are registered trademarks of Genomic Health, Inc. Exact Sciences is a registered trademark of Exact Sciences Corporation. © 2021 Genomic Health, Inc. All rights reserved. EXS11450_1121_EN_INT